Skip to main content

Definitive Healthcare Corp.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

DH$1.19+6.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Six Months Ended June 30,
20262025
Cash flows provided by (used in) operating activities:
Net loss$(199,806)$(164,358)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization2,0741,459
Amortization of intangible assets24,95326,696
Amortization of deferred contract costs7,4397,935
Equity-based compensation10,47414,299
Amortization of debt issuance costs340249
Recovery of doubtful accounts receivable(192)(321)
Loss on partial extinguishment of debt—507
Non-cash restructuring charges183192
Goodwill impairment charges197,219176,531
Tax Receivable Agreement remeasurement(6,585)(17,763)
Changes in fair value of contingent consideration—(690)
Deferred income taxes(4,002)(10,609)
Changes in operating assets and liabilities:
Accounts receivable21,22315,874
Prepaid expenses and other assets(949)(4,230)
Deferred contract costs(5,787)(6,259)
Accounts payable, accrued expenses, and other liabilities(13,537)(12,145)
Deferred revenue(10,027)8,003
Net cash provided by operating activities23,02035,370
Cash flows (used in) provided by investing activities:
Purchases of property, equipment, and data assets(6,144)(9,999)
Purchases of short-term investments(12,500)(64,065)
Maturities of short-term investments17,326147,447
Net cash (used in) provided by investing activities(1,318)73,383
Cash flows (used in) provided by financing activities:
Repayments of term loan(4,375)(248,438)
Proceeds from term loan—175,000
Payments of debt issuance costs—(1,660)
Taxes paid related to net share settlement of equity awards(1,446)(2,483)
Repurchases of Class A common stock—(40,231)
Payments under Tax Receivable Agreement(8,077)(13,767)
Member distributions—(2,827)
Net cash used in financing activities(13,898)(134,406)
Net increase (decrease) in cash and cash equivalents7,804(25,653)
Effect of exchange rate changes on cash and cash equivalents(565)1,259
Cash and cash equivalents, beginning of period163,627105,378
Cash and cash equivalents, end of period$170,866$80,984
Supplemental cash flow disclosures:
Cash paid during the period for:
Interest$4,918$5,201
Income taxes, net of refunds received$200$32
Supplemental disclosure of non-cash investing activities:
Capital expenditures included in accounts payable and accrued expenses and other liabilities$2,926$4,947
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.